Radiopharm Doses First Patient in Phase I Prostate Cancer Radiotherapy Study
Alpha‑Emitting PSMA Therapies Gain Momentum Across Radiopharma Leaders
Ratio Therapeutics Highlights the Next Wave of Radiopharmaceutical Manufacturing Standards
Radiopharma Veterans From Novartis‑Built Platforms Strengthen Emerging Biotechs
Radiopharma Takes Center Stage as Global Biopharma Partnering Accelerates

Benjamin Titz

Benjamin Titz

Co-Founder & CEO Alkyon Therapeutics

Seminars

Thursday 23rd July 2026

Linking Biodistribution to Efficacy in Radioligand Therapy: Insights & Limitations from Preclinical Dosimetry

Benjamin Titz - Co-Founder and Chief Executive Officer, Alkyon Therapeutics - Expert Speaker at the 5th Targeted Radiopharmaceuticals Summit US 2026, San Diego, CA

View all Speakers

View Event Brochure